1. Introduction {#sec1}
===============

Defects in Ca^2+^ release by the cardiac ryanodine receptor (RyR2) is associated with many heart diseases including catecholaminergic polymorphic ventricular tachycardia (CPVT), catecholaminergic idiopathic ventricular fibrillation, malignant hyperthermia, and central core disease.^[@ref1]−[@ref3]^ The first-line medications for most cardiac diseases include β-blockers or calcium channel blockers.^[@ref4]^ However, these medications have serious limitations including proarrhythmic potential and drug toxicity. The newer targets for anti-arrhythmic treatment include acting upon intracellular Ca^2+^ handling in the cardiac myocyte, interference with the Ca^2+^/calmodulin-dependent protein kinase II, the Na^+1^/Ca^2+^ exchanger, RyR, and the late component of Na current (*I*~Na-Late~).^[@ref5]^ Ca^2+^ release from RyR2 is partly regulated by cardiac calsequestrin (CASQ2), the major Ca^2+^-buffering protein in the sarcoplasmic reticulum (SR).^[@ref6]^ CASQ2 binds Ca^2+^ with high capacity and low affinity,^[@ref7],[@ref8]^ which allows quick dissociation of Ca^2+^ for release via RyR2, thereby facilitating repetitive muscle contractions.^[@ref9],[@ref10]^ CASQ2 interaction with RyR2 is complex, and different (both direct and indirect) mechanisms were proposed.^[@ref6],[@ref11]^ Györke and Györke suggested that the action of the RyR is directed by CASQ, which can sense changes in luminal Ca^2+^ concentration in the range of 0.2--20 mM. Alternatively, CASQ2 might serve only as a fast source of Ca^2+^ ions near the RyR2 channel. In this case, CASQ2 would regulate the Ca^2+^ current flowing via the RyR2 channel. They further explained that it might be important to regulate Ca^2+^ release under normal and pathological conditions.^[@ref12]^ Moreover, Terentyev et al. indicated that CASQ2 controls the magnitude and duration of Ca^2+^ release^[@ref23]^ and thereby affects the luminal Ca^2+^-dependent RyR2. Approximately 15 mutations in CASQ2 were reported to cause a unique type of arrhythmia called CPVT. These mutations (L167H, D307H, P308L, and R33Q) affect Ca^2+^-induced CASQ2 polymerization that impairs RyR2-mediated Ca^2+^ release in the subsequent contraction--relaxation cycle leading to sudden cardiac death.^[@ref13]−[@ref21]^ Further, ablation of CASQ2 is known to cause CPVT in a mouse model.^[@ref22]^ We therefore propose that targeting modulation of CASQ2 polymerization by a small molecule could be an attractive drug target for treating CPVT and possibly other forms of arrhythmia.^[@ref23]^

Different classes of small molecules with varied biological significance were shown to bind to CASQ2 based on docking, X-ray crystallography, and biological studies.^[@ref24]−[@ref26]^ Some of the molecules bind to CASQ2 and cause destabilization of the polymeric state,^[@ref24]^ while others induce polymerization.^[@ref26]^ Anthracyclines (doxorubicin, doxorubicinol, daunorubicin, daunorubicinol) and phenothiazines (promethazine, thioridazine, chlorpromazine) are reported to have affinity for CASQ2, affect Ca^2+^-induced CASQ2 polymerization, and alter SR-mediated Ca^2+^ release.^[@ref27],[@ref28]^ However, anthracyclines are known to cause cardiotoxicity.^[@ref29]^ It was proven that addition of doxorubicin triggers Ca^2+^ release from cardiac SR vesicles^[@ref30]−[@ref32]^ Pessah et al. reported that the anthracyclines enhanced \[3*H*\]ryanodine binding to rat SR vesicles enriched in RyR2 channels. They further suggested that, with the interaction of anthraquinones, there is a receptor-mediated shift in the redox equilibrium of allosteric thiols in RyR.^[@ref33]^ Anthracycline--RyR2 interaction is mediated by the presence of quinone and a side-chain carbonyl, which interacts with the cysteine residues in the cytosolic RyR2 face.^[@ref34]^ Further, human carbonyl reductase induces one-electron reduction of quinone and two-electron reduction of side-chain carbonyl, and these are accompanied by iron and free radical reactions.^[@ref35]^ The effect of the anthracycline metabolite is even more pronounced than the anthracycline itself. It decreases the extent of CASQ2 linked with RyR2, and it also interacts directly with CASQ2 to induce structural changes due to lower Ca^2+^ binding capacity.^[@ref34]^ We aimed to design a molecule without a quinone moiety with the ability to interact with CASQ2 that does not induce oxidative stress forming metabolites, which could lead to toxicity. The ester/amide group requires harsh conditions for its reduction in comparison to aldehyde and ketone and hence is less likely to produce alcohol metabolites to interfere with the thiol residues of RyR2.

Herein, we report synthesis of derivatives based on a new scaffold, namely, 4,6-disubstituted-2*H*-pyranone-3-carbonyl-glycinate/alaninate/acetate, earlier unknown to interfere with CASQ2 polymerization. We hypothesize that molecules belonging to this novel class may stabilize the CASQ2 polymer in an arrhythmic condition.

2. Results and Discussion {#sec2}
=========================

2.1. Synthesis {#sec2.1}
--------------

The 6-aryl-4-methylthio-2*H*-pyranone-3-carboxylic acids (**1a**--**e**) were synthesized from various substituted acetophenones or 2-acetyl furan ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}) according to our reported procedure from ketene dithioacetals and diethyl malonate (DEM).^[@ref36],[@ref37]^ Ethyl 6-aryl-4-(methylthio)-2-oxo-2*H*-pyran-3-carboxylate (**1f**) was formed as a minor product during the synthesis of **1b**. Generally, in the synthesis, deprotonated DEM forms a new C--C bond with a ketene dithioacetal upon the elimination of the SMe^--^ group and subsequent deprotonation followed by the release of the ethoxide anion leading to the formation of the ethyl ester derivative of pyranone carboxylic acid, which upon hydrolysis affords the corresponding 3-carboxylic acid derivatives (**1a**--**e**) with 36--54% yields (see [Figure S1](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b01113/suppl_file/ao9b01113_si_001.pdf)). Glycine/alanine ester was coupled with **1a**--**e** to generate 6-aryl-4-methylthio-2*H*-pyranone-3-carbonyl glycinate/alaninate key intermediates (**2a**--**e**, details in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b01113/suppl_file/ao9b01113_si_001.pdf)) in the presence of hexafluorophosphate azabenzotriazole tetramethyl uronium (HATU) as the coupling agent and *N*,*N*-diisopropylethylamine (DIPEA) as the base with 85--91% yields. The reaction when performed using *N*,*N*′-dicyclohexylcarbodiimide (DCC) as a coupling reagent resulted in lower yields along with additional purification steps. The final 4,6-disubstituted-2*H*-pyranone-3-carbonyl-glycinates/alaninates/acetates (**3a**--**x**, [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) were obtained by nucleophilic substitution of **2a**--**e**/**1f** with appropriate amine in ethanol. All synthesized compounds were characterized (data in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b01113/suppl_file/ao9b01113_si_001.pdf)) by melting point, IR, UV, MS, and ^1^H/^13^C NMR. In addition, one of the final compounds (**3b**) was analyzed by single-crystal X-ray diffraction. ORTEP diagram (Oak Ridge thermal ellipsoid plot) is presented in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}. CCDC-150756 (The Cambridge Crystallographic Data Centre) contains the supplementary crystallographic data for this paper.

![Structures of synthesized pyranone derivatives.](ao-2019-011138_0002){#fig1}

![ORTEP diagram drawn with 50% thermal ellipsoidal probability with atom numbering scheme of compound **3b** (CCDC No: 150756).](ao-2019-011138_0007){#fig2}

![Synthesis of 4,6-Disubstituted-2*H*-pyranone-3-carbonyl-glycinate/alaninate/acetate (**3a**--**x**)\
Reagents and conditions: (i) glycine/alanine ester, HATU, DIPEA, DCM, rt, 3--4 h; (ii) aliphatic amine, ethanol, reflux, 2--6 h.](ao-2019-011138_0003){#sch1}

2.2. Biological Evaluation {#sec2.2}
--------------------------

A Ca^2+^-induced aggregation of CASQ2 followed by the ethylene glycol tetraacetic acid (EGTA)-mediated resolubilization/depolymerization assay^[@ref20]^ was used for evaluating the ability of **3a**--**x** to modulate the polymeric state of CASQ2 ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). EGTA has much higher affinity for Ca^2+^ than CASQ2. Therefore, Ca^2+^ chelation with EGTA compels CASQ2 polymers to release a portion of the bound Ca^2+^ with or without depolymerization. The concentrations of EGTA to resolubilize 50% of CASQ2 protein from aggregation (i.e., EC~50~ of EGTA-mediated resolubilization) in the absence and presence of any one of **3a**--**x** at a time in a specified concentration were measured. Compounds at concentration 1 μM or less necessitating higher concentration of EGTA for resolubilization of CASQ2 are considered to inhibit its depolymerization ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). Percentage inhibition of CASQ2 depolymerization by a compound is the ratio of the percentage of CASQ2 left as polymer in its presence to the percentage of CASQ2 left as polymer in its absence at a particular EGTA concentration.

![Colored heatmap visualizing the results of EGTA-mediated resolubilization/depolymerization assay. Concentration values are scaled by row. Compound code is indicated in the *x* axis. Compounds **3e**, **3u**, and **3v** have the highest potentials (\>50% at 100 nM) to inhibit depolymerization of CASQ2.](ao-2019-011138_0006){#fig3}

2.3. Molecular Modeling {#sec2.3}
-----------------------

Blind docking of the most active molecules **3e**, **3u**, and **3v** to the two dimers indicated the clear preference for the front-to-front dimer. Over 250 poses grouped into nearly 33 clusters were generated for each structure docked into both dimers. The top six clusters generated from docking into the front-to-front dimer suggested its binding into the interface of the two monomers ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}). Meanwhile, we could not identify a specific preference for any binding site in the back-to-back dimer. We therefore examined the binding site at the interface of the front-to-front dimer in details. The CASQ2 monomer is composed of three thioredoxin folds connected by loops. The binding pocket is formed between the residues of the two monomers. The molecules were found to interact with the N-terminal, the first thioredoxin fold of the first monomer, and the third thioredoxin fold of the second monomer ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}). The aliphatic amine forms a H-bonding interaction with His67 of one monomer, and Ar--F is involved in electrostatic interactions with Leu294 of the second monomer ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}). It is further stabilized by the hydrophobic interactions with several residues including Ala297, Lys301, and Tyr298 of the first and Leu65, Val64, and Glu66 of the second monomer, respectively. The ester/amide group is projected outward from the protein without actually participating in the binding. The binding of the molecules provides additional arms to hold the monomers together and prevent the Ca^2+^ leak in an arrhythmic condition.

![Compound **3u** is bound at the interface of CASQ2 dimer (1SJI). (A) Electrostatic surface image of the binding site. The ester group is projected out of the protein surface. (B) Binding mode of **3u** in CASQ2 dimer. The amine group forms H-bonding interaction with the first monomer, and Ph--F is involved in electrostatic interaction with the second monomer. The molecule forms several hydrophobic interactions with Ala297, Lys301, and Tyr298 of the first and Leu65, Val64, and Glu66 of the second monomer holding the two monomers together. The model was created using Maestro. The ligand is represented using ball and stick, and the interacting residues are represented in line notation. The protein structure is represented in ribbon.](ao-2019-011138_0005){#fig4}

Fifteen molecules out of **3a**--**x** ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}) were able to inhibit depolymerization of CASQ2 at a concentration below 10 μM and considered active. Among them, molecules with an ability to inhibit more than 50% CASQ2 depolymerization at 100 nM were considered highly active. Compounds **3a**--**c** with an unsubstituted phenyl ring at the C-6 position were found to be inactive. It was found that the 4-F-phenyl at the C-6 position enhances activity when the C-4 position contains a primary amine with acyclic alkyl group. **3e**, **3u**, and **3v** ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}) were able to inhibit more than 50% CASQ2 depolymerization at 100 nM, and **3m** inhibited more than 50% CASQ2 depolymerization at 250 nM. When we replaced 4-F-phenyl with furan-2-yl, 4-Cl-phenyl, 4-Br-phenyl, or the primary amine at the C-4 position, we observed a considerable decrease in activity in the resulting compounds ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). Among the 24 molecules, only those molecules with open-chain amine at C-4 and 4-F-phenyl at the C-6 showed the high inhibitory effect ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). The structure--activity relationship (SAR) of the synthesized pyranone analogs is summarized in [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}.

![Structure--activity relationship of synthesized pyranone derivatives.](ao-2019-011138_0001){#fig5}

3. Conclusions {#sec3}
==============

In conclusion, we have discovered the pyranone analogs as promising new chemotypes with the ability to stabilize the CASQ2 polymer. Twenty-four glycinate/alaninate/acetate pyranone analogs were synthesized and evaluated for CASQ2 polymer stabilization potential. SAR studies revealed that the 4-F-phenyl at the 6th position of the pyranone ring and open-chain primary amine at the 4th position were the most active of the class. Docking studies suggest that the molecules interact at the interface of the front-to-front dimer, which is the first key step in CASQ2 polymerization and is determinant of its rate. The present work opens an avenue for further research toward targeting CASQ2 polymerization to treat CPVT and other forms of arrhythmia by describing a new class of molecules and revealing the potential drug binding pocket in the CASQ2 that stabilizes its polymer.

4. Experimental Section {#sec4}
=======================

4.1. Chemistry {#sec4.1}
--------------

General: All the reactions were carried out in oven-dried glassware. The chemicals and solvents were purchased from Sigma-Aldrich, Spectrochem, or Acros and were used without any purification except THF (tetrahydrofuran), which was dried by refluxing over sodium followed by distillation. Reactions were monitored by TLC, which are precoated by silica gel (Kieselgel 60F 254, Merck), and the spots were detected under UV light (254 nm). Compounds were purified by column chromatography using silica gel (particle size 100--200 mesh). ^1^H and ^13^C NMR spectra were characterized in CDCl~3~ or DMSO-*d*~6~ solution by using (Wormhole-vnmrs/Bruker/Jeol-Delta/Varian) 400/300 MHz spectrophotometers. Chemical shifts are reported as ppm (δ) relative to TMS (δ 0.0) as the internal standard. ^1^H NMR data is recorded as follows: chemical shift \[multiplicity, coupling constant(s) *J* (Hz), relative integral\] where multiplicity is defined as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), and bs (broad singlet). Mass spectra were recorded on a 6430 Triple quardrupole mass spectrometer for ESI and are given in *m*/*z*. FTIR spectra were recorded on a PerkinElmer 1600 series FTIR spectrophotometer. UV spectra were recorded on a PerkinElmer Lambda 25 UV--visible spectrophotometer (USA).

### 4.1.1. Synthesis of the Amides **2a**--**e** {#sec4.1.1}

General Procedure: To a solution of appropriate **1a**--**e** (2.02 mmol) in 10 mL of dichloromethane (DCM) at room temperature (rt, 15--35 °C), HATU (2.05 mmol) was added and stirred for 10 min. DIPEA (7.6 mmol) was added and stirred for another 15 min. Thereafter, glycine/alanine ester (2.05 mmol) was added and stirred for a further 2 h at rt. The reaction was monitored by TLC for completion and then was washed with water and brine subsequently. DCM was evaporated, and the crude product was purified by column chromatography by eluting with an ethyl acetate/hexane mixture to obtain **2a**--**e** with \>80% yields.

#### 4.1.1.1. Methyl (4-(Methylthio)-2-oxo-6-phenyl-2*H*-pyran-3-carbonyl)glycinate (**2a**) {#sec4.1.1.1}

Yellow crystalline powder; yield 88%; mp: 175--176 °C; IR (KBr) (ν, cm^--1^) 3310 (N--H), 1744, 1686, and 1639 (C=O); UV (MeOH) λ~max~ = 252.7, 336.8 nm; MS-ESI (*m*/*z*): \[M^+^\] = 333.9; ^1^H NMR (400 MHz, DMSO-*d*~6~) δ 2.60 (s, 3H, SMe), 3.66 (s, 3H, OC*H*~3~), 4.06--4.07 (d, *J* = 6.0 Hz, 2H, NC*H*~2~), 7.18 (s, 1H, pyranone-*H*), 7.59--7.62 (m, 3H, Ar*H*), 8.02--8.05 (m, 2H, Ar*H*), 9.23--9.26 (t, *J* = 6.0 Hz, 1H, N*H* amide); elemental analysis: C: 57.73, H: 4.62, N: 4.13, S: 9.43.

### 4.1.2. Synthesis of the Final Compounds **3a**--**x** {#sec4.1.2}

To a solution of appropriate **2a**--**e**/**1f** (1.5 mmol) in ethanol, corresponding amine (RNH~2~, 2.2 mmol) was added and refluxed for 2 h. The completion of the reaction was monitored by TLC. Ethanol was removed under reduced pressure (\<100 mbar). The crude was dissolved in DCM and washed with water and brine, and the organic layer was concentrated under reduced pressure (\<800 mbar). The crude was purified using column chromatography by eluting with a mixture of hexane and ethyl acetate to get **3a**--**x** in 40--65% yields.

#### 4.1.2.1. Methyl (6-(4-Bromophenyl)-4-(cyclopropylamino)-2-oxo-2*H*-pyran-3-carbonyl)glycinate (**3p**) {#sec4.1.2.1}

White powder; yield 65%; mp: 180--183 °C; IR (KBr) (ν, cm^--1^): 1759, 1682, 1639 (C=O stretching), 3333 (N--H stretching), 3078 (C--H); UV (MeOH) λ~max~ = 227.9, 248.3, 311.7 nm; MS-ESI (*m*/*z*): \[M^+^ + 1\] 422.8; ^1^H NMR (400 MHz, CDCl~3~) δ 0.74--0.77 (m, 2H, C*H*~2~), 0.93--0.98 (m, 2H, C*H*~2~), 2.67--2.69 (m, 1H, C*H*), 3.77 (s, 3H, OC*H*~3~), 4.10--4.12 (d, *J* = 5.6 Hz, 2H, C*H*~2~), 6.91 (s, 1H, pyranone-*H*), 7.61--7.63 (m, 2H, Ar*H*), 7.73--7.75 (m, 2H, Ar*H*), 9.69--9.71 (t, *J* = 5.6 Hz, 1H, CON*H*), 11.06 (bs, 1H, N*H*); ^13^C NMR (75 MHz, CDCl~3~) 7.73, 24.54, 41.01, 52.29, 86.52, 94.11, 126.35, 127.66, 129.86, 132.28, 159.45, 162.74, 163.42, 169.22, 170.40.

4.2. Depolymerization Assay {#sec4.2}
---------------------------

The rat wild-type (WT) CASQ2 was cloned into a pET21a vector (Novagen) between Nde I and Xho I restriction sites. The protein was expressed in bacterial cells and purified using an earlier published method.^[@ref18]^ To a 2.5 μM CASQ2 solution in 50 mM Tris-HCl buffer (pH 7.5) containing 20 mM NaCl at 25 ± 2 °C, **3a** was added at specified concentration. To this solution, 10 mM CaCl~2~ was added to polymerize the protein. The solution was left to stand for 1 h, thereafter it was mixed by pipetting and aliquot of 500 μL were pipetted into new test tubes. One of these test tubes was centrifuged at 20000*g* for 1 h, and absorbance was recorded at 350 nm. The soluble fraction was estimated for protein concentration by the Bradford reagent (Bio-Rad) following the manufacturer's protocol. This was performed to confirm that more than 75% of proteins were polymerized. To the polymerized solution aliquots in several test tubes, 2--10 μL of EGTA (0.1--0.5 M) was added and allowed to equilibrate for 30 min. Then absorbance was recorded at 350 nm, and the percentage of protein still polymerized in different tubes was calculated as above. The concentration of EGTA to resolubilize 50% of CASQ2 protein from precipitation (i.e., EC~50~ of EGTA-mediated resolubilization) was calculated. EC~50~ of **3a** at specified concentration was compared to EC~50~ in sample buffer. This procedure was repeated for the rest of the compounds (**3b**--**x**). The percentage of inhibition was calculated by taking the ratio between the percentage left as polymer with and without the chemical compound at a particular EGTA concentration.

4.3. Molecular Modeling {#sec4.3}
-----------------------

In silico molecular docking was performed to understand the possible binding site of our designed molecules. CASQ2 polymers are formed via front-to-front (N-terminal) and back-to-back (C-terminal) contacts.^[@ref38]^ The structure for the front-to-front dimer is established; however, not much information is available for the back-to-back dimer (C-terminal contact points) due to the absence of a crystal structure. In order to facilitate polymerization, it is plausible that these molecules interact at the polymeric interface. Since there was no prior knowledge about the binding site of the molecules, blind docking was performed using web server Swiss Model^[@ref39]^ with the accurate mode. The crystal structure of the front-to-front dimer 1SJI was downloaded from the RCSB protein data bank (<http://www.rcsb.org/>). The structure is devoid of intrinsically disordered C-terminal residues; however, it does not make a significant contribution in the protein folding.^[@ref40]^ The protein structure was prepared using the default parameters of Protein Preparation Wizard of the Schrödinger Suite.^[@ref41]^ As there was no information about any conserved water molecules, the water molecules were deleted. The structures of the most active molecules **3e**, **3u**, and **3v** were provided after minimization with the OPLS3e force field, run for a maximum of 25000 iterations using the MacroModel module of the Schrödinger Suite. To examine if the molecules bind to the back-to-back interface of the CASQ2 structure, we built the homology model of the back-to-back dimeric CASQ2 structure. We used the sequence of 1SJI for building the model. The 3D-homology model of the CASQ2 back-to-back dimer was built using the Prime module of the Schrödinger Suite. Chains B and C of the crystal structure of human CASQ1 (PDB code 3UOM) was chosen as the template. 3UOM is the polymeric structure of CASQ, which is very likely to resemble the CASQ2 polymeric structure. The sequence alignment shows 68% identity and 84% positives. 3UOM is a hexamer composed of six chains A--F. The dimeric units AB, CD, and EF are involved in the front-to-front contact, and the dimeric units BC and DE have the back-to-back contacts. The homology model obtained was minimized, and loops were refined using the default parameters of Prime minimization and loop refinement. The structure hence obtained was used for blind docking using accurate mode of Swiss Dock. The results were analyzed using UCSF Chimera (<https://www.cgl.ucsf.edu/chimera/>). Binding mode was further analyzed using the Discovery Studio Visualizer.^[@ref42]^

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.9b01113](http://pubs.acs.org/doi/abs/10.1021/acsomega.9b01113).Analytical data and experimental procedures for all the compounds ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b01113/suppl_file/ao9b01113_si_001.pdf))
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